Our Pricing

How Long Does Wegovy Stay in Your System?

Published on: June 03, 2026

Understanding how long does Wegovy stay in your system is essential for managing side effects, planning treatment breaks, or switching medications. Wegovy (semaglutide) has a half-life of approximately 7 days, meaning it takes around 5 weeks for the medication to be fully eliminated from your body after your final injection [1]. At Cured Pharmacy, our UK-registered clinical team provides comprehensive guidance on Wegovy treatment, from initiation through to discontinuation, with prices starting from £79.00.

Wegovy Half-Life and Elimination Timeline

Wegovy contains semaglutide, a GLP-1 receptor agonist with an extended half-life of approximately 7 days [1]. This prolonged half-life allows for once-weekly dosing but also means the medication remains in your system significantly longer than daily treatments like Saxenda (liraglutide), which has a half-life of just 13 hours [2].

Pharmacokinetic studies show that it takes approximately 4 to 5 half-lives for a medication to be considered fully eliminated from the body [1]. For Wegovy, this translates to roughly 5 weeks (35 days) after your last injection before semaglutide is no longer detectable in your bloodstream. During this washout period, you may continue to experience both therapeutic effects and potential side effects as drug levels gradually decline.

The elimination process follows predictable pharmacokinetics: after one week, approximately 50% remains; after two weeks, 25%; after three weeks, 12.5%; and so on until complete clearance [1]. This gradual reduction explains why side effects typically diminish slowly rather than stopping abruptly when treatment is discontinued.

Factors That Affect How Long Wegovy Stays in Your System

While the average elimination timeline is consistent across most patients, several physiological factors can influence how quickly your body processes semaglutide. Renal function plays a minimal role, as Wegovy is primarily metabolised through proteolytic cleavage rather than kidney excretion, meaning patients with mild to moderate kidney impairment typically show similar elimination rates [3].

Body weight and composition can affect distribution volume, though clinical trials have not shown clinically significant differences in half-life across different BMI categories [1]. Age also has minimal impact on semaglutide pharmacokinetics, with elderly patients showing comparable elimination profiles to younger adults in STEP trial analyses [4].

Your prescribed dose does influence total drug exposure but not the elimination rate itself. Whether you're on the maintenance dose of 2.4 mg or a lower titration dose, the half-life remains approximately 7 days. However, higher doses naturally result in higher peak concentrations, which take the same proportional time to decline to undetectable levels.

Medical Conditions and Wegovy Clearance

Hepatic impairment has not been shown to significantly alter semaglutide pharmacokinetics in clinical studies, as the medication is not hepatically metabolised through cytochrome P450 pathways [3]. Similarly, thyroid function, diabetes status, and cardiovascular conditions do not meaningfully change how long Wegovy stays in your system, though these conditions may influence treatment suitability and require careful monitoring by your UK prescriber.

Side Effects During the Elimination Period

Common gastrointestinal side effects such as nausea, vomiting, diarrhoea, and constipation typically persist during the early elimination phase, gradually diminishing as semaglutide concentrations decline [4]. In the STEP clinical trials, patients who discontinued treatment reported that most side effects resolved within 2 to 3 weeks, though some individuals experienced symptoms for up to 4 weeks post-discontinuation [4].

Appetite suppression, one of Wegovy's primary therapeutic mechanisms, follows a similar timeline. Most patients notice their appetite beginning to return within 10 to 14 days after their last injection, with full normalisation typically occurring by week 3 or 4. This gradual return can be beneficial for patients who experienced excessive appetite suppression or difficulty maintaining adequate nutrition during treatment.

Rare but serious side effects such as pancreatitis symptoms or severe allergic reactions require immediate medical attention regardless of when they occur relative to your last dose. If you develop severe abdominal pain, persistent vomiting, or signs of an allergic reaction during the elimination period, contact your GP or call 111 immediately, even if you've already stopped treatment.

Managing Symptoms After Stopping Wegovy

If you're discontinuing Wegovy due to side effects, your UK prescriber may recommend symptomatic management during the washout period. Anti-emetics can help with persistent nausea, while dietary modifications such as smaller, more frequent meals may ease gastrointestinal discomfort. Staying well-hydrated remains important throughout the elimination phase, particularly if you've experienced vomiting or diarrhoea.

Switching from Wegovy to Other Weight Loss Treatments

When transitioning from Wegovy to another GLP-1 receptor agonist like Saxenda or Mounjaro, your prescriber will consider the overlapping pharmacological effects. Because Wegovy remains active in your system for several weeks, starting another GLP-1 treatment immediately may increase the risk of gastrointestinal side effects due to additive mechanisms [2].

For patients switching to Mounjaro (tirzepatide), which acts on both GLP-1 and GIP receptors, most UK prescribers recommend waiting at least 1 to 2 weeks after your last Wegovy dose before initiating the new treatment [5]. This allows semaglutide levels to decline sufficiently while minimising the treatment gap. The exact timing depends on your tolerance to side effects and clinical circumstances.

Switching to non-GLP-1 treatments such as Orlistat or Mysimba typically does not require a washout period, as these medications work through entirely different mechanisms. Your prescriber can initiate these alternatives immediately if clinically appropriate, though they'll monitor for any unexpected interactions during the transition.

Weight Regain After Stopping Wegovy

Clinical evidence from the STEP trial extension studies shows that patients who discontinue Wegovy typically experience gradual weight regain over the following months [4]. In one analysis, participants regained approximately two-thirds of their lost weight within one year of stopping treatment, highlighting the importance of long-term lifestyle modifications alongside pharmacotherapy.

The initial weeks after your last dose represent a critical period for weight management. As appetite returns and metabolic effects wane, focusing on established healthy eating patterns and regular physical activity becomes essential. Many patients find that the behavioural changes developed during treatment, such as portion control and mindful eating, help mitigate weight regain even as the medication clears from their system.

If you're considering stopping Wegovy, discuss a comprehensive weight maintenance plan with your prescriber. This may include continued dietary support, exercise programmes, or transitioning to an alternative weight management medication. At Cured Pharmacy, our clinical team can assess your suitability for alternative treatments, including Mounjaro from £79.00, Saxenda from £79.00, or oral options like Orlistat from £79.00, all subject to prescriber approval.

Long-Term Weight Management Strategies

Research indicates that combining pharmacotherapy with structured lifestyle interventions produces superior long-term outcomes compared to medication alone [4]. Consider working with a registered dietitian or enrolling in a behavioural weight management programme during your treatment and through the discontinuation period. These supportive measures can help preserve weight loss achievements as Wegovy gradually leaves your system.

Restarting Wegovy After a Treatment Break

If you need to restart Wegovy after a break of 5 weeks or longer, when the medication has fully cleared your system, you'll typically need to repeat the dose escalation schedule rather than resuming at your previous maintenance dose [1]. This gradual titration minimises gastrointestinal side effects and allows your body to readjust to semaglutide's effects.

The standard Wegovy titration follows a monthly progression: 0.25 mg for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg as the maintenance dose. Your UK prescriber may modify this schedule based on your tolerance, previous experience with the medication, and how long you've been off treatment. Patients who stopped due to side effects may benefit from a slower escalation or lower maintenance dose.

For shorter treatment interruptions of less than 2 weeks (such as missing one or two doses), the manufacturer guidance suggests resuming at your current dose without restarting titration [1]. However, if you've missed more than 2 consecutive doses, consult your prescriber before resuming, as individual circumstances vary and clinical judgement is essential for safe reinitiation.

Scientific References

1. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Kalra, S., Barakatun-Nisak, M. Y., Sahay, R., Czupryniak, L., Haddad, J., & Mansour, M. (2016). Liraglutide in clinical practice: A review. Diabetes Therapy, 7(3), 387–402. https://doi.org/10.1007/s13300-016-0179-6 [accessed 13 August 2026]
3. Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-4 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.